Pharmaceutical Commerce

Featured Content

Pharmaceutical Commerce - December 2023

Click here to read the articles and download the PDF

The Business Case for RWE

How drugmakers can better harness real-world evidence to drive their clinical and commercial objectives, while also providing greater clarity for healthcare providers and improved access to therapy for the patients they serve.

Who Moved My Prescription?

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

Transforming the Patient Hub into a Hub of Patient Centricity

Methods that pharma companies can use to make the hub more personalized and experiential.

Obesity Treatment Zepbound Now Available in United States

December 05, 2023

Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.

Investigational Treatment for High-Risk Bladder Cancer Awarded FDA Breakthrough Designation

December 05, 2023

Johnson & Johnson’s TAR-200 has a novel targeted releasing system that allows for a controlled release of gemcitabine in patients with Bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.

Opdivo Combination Granted FDA Priority Review for Unresectable, Metastatic Urothelial Carcinoma

December 05, 2023

Opdivo (nivolumab) plus cisplatin-based chemotherapy shows improved survival benefits in the first-line treatment of adults with unresectable or metastatic urothelial carcinoma.

Generative Artificial Intelligence Could Transform Healthcare if Challenges Are Addressed

December 04, 2023

Critical factors need to be addressed for pharma stakeholders to realize the full potential of generative artificial intelligence.

FDA Grants Pirtobrutinib Accelerated Approval for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

December 04, 2023

Jaypirca (pirtobrutinib) is indicated for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who received at least two prior lines of treatment with a Bruton tyrosine kinase inhibitor and a BCL2 inhibitor.

Triplet Combination for Breast Cancer Gets FDA Fast Track Designation

December 01, 2023

Ongoing clinical trials are evaluating zotatifin (eFT226) plus Faslodex (fulvestrant) and Verzenio (abemaciclib) for the treatment of ER–positive, HER2-negative advanced or metastatic breast cancer.

FDA Priority Review Granted to Keytruda/Padcev Combo for Locally Advanced, Metastatic Urothelial Carcinoma

December 01, 2023

In clinical trials, Keytruda plus Padcev lowered the risk of disease progression or death by 55% compared with chemotherapy in adult patients with locally advanced or metastatic urothelial carcinoma.

Priothera's Mocravimod Granted to Orphan Drug Designation to Improve Post-Stem Cell Transplant Outcomes

November 30, 2023

Sphingosine-1-phosphate receptor modulator is designed to improve leukemia-free survival by increasing graft-versus-leukemia response.

Arcutis Biotherapeutics Seeks FDA Approval for Roflumilast in Atopic Dermatitis

November 30, 2023

In clinical trials, roflumilast cream demonstrated rapid and sustained improvement in the signs and symptoms of atopic dermatitis in patients 6 years of age and older.

Cryoport, Nippon Express Establish Supply Chain Services Collaboration

November 30, 2023

The companies will partner up to design and implement solutions that support each other's business efforts.